(Q43031360)

12 November 2017

title

Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life (English)

1 reference

12 November 2017

1 reference

1

1 reference

12 November 2017

Rosenthal E

2

1 reference

12 November 2017

Halfon P

3

1 reference

12 November 2017

Sene D

4

1 reference

12 November 2017

Perronne C

5

1 reference

12 November 2017

Pol S

6

1 reference

12 November 2017

publication date

1 October 2006

1 reference

Journal of Viral Hepatitis

12 November 2017

published in

1 reference

12 November 2017

volume

13

1 reference

12 November 2017

issue

10

1 reference

12 November 2017

page(s)

678-682

1 reference

Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997.

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00740.X

Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00740.X

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00740.X

Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00740.X

Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00740.X

Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00740.X

Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00740.X

Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00740.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00740.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00740.X

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00740.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00740.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00740.X

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00740.X

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00740.X

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00740.X

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00740.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00740.X

Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00740.X

Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: need for team care

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00740.X

Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00740.X

Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00740.X

Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00740.X

Integrating treatment for hepatitis C virus infection into an HIV clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00740.X

Care of patients with hepatitis C and HIV co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00740.X

Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00740.X

10.1111/J.1365-2893.2006.00740.X

21 January 2018

Identifiers

DOI

1 reference

release_ecyr4fd7fjho5bh4hpt3jljy44

12 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ecyr4fd7fjho5bh4hpt3jljy44

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference